Article Text

other Versions

Download PDFPDF
Randomised controlled trial
Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment
  1. Timothy R Sterling
  1. A2209 Medical Center North, Nashville, Tennessee, USA
  1. Correspondence to: Dr Timothy Sterling, A2209 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232, USA; timothy.sterling{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: Study 1: OpenUrlCrossRefPubMedWeb of Science

Study 2: Merle CS, Fielding K, Sow OB, et al; OFLOTUB/Gatifloxacin for Tuberculosis Project. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371:1588–98.

Study 3: Jindani A, Harrison TS, Nunn AJ, et al; RIFAQUIN Trial Team. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371:1599–608.


Current antituberculosis therapy is a 6-month regimen that includes 2 months of isoniazid, rifampin, pyrazinamide and ethambutol, followed by 4 months of …

View Full Text


  • Competing interests TS serves on a data safety monitoring board for a clinical trial sponsored by Otsuka.

  • Provenance and peer review Commissioned; internally peer reviewed.